Clinical Trial Update: Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating liposomal doxorubicin followed by bexarotene for cutaneous T-cell lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Bexarotene (Bexarotene)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-08-16